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Abstract
TAB1 was defined as a regulatory subunit of the protein kinase TAK1, which functions upstream in the pathways activated
by interleukin (IL)-1, tumor necrosis factor (TNF), toll-like receptors (TLRs) and stressors. However, TAB1 also functions in the
p38 MAPK pathway downstream of TAK1. We identified amino acids (aa) 452/453 and 456/457 of TAB1 as novel sites
phosphorylated by TAK1 as well as by p38 MAPK in intact cells as well as in vitro. Serines 452/453 and 456/457 were
phosphorylated upon phosphatase blockade by calyculin A, or in response to IL-1 or translational stressors such as
anisomycin and sorbitol. Deletion or phospho-mimetic mutations of aa 452–457 of TAB1 retain TAB1 and p38 MAPK in the
cytoplasm. The TAB1 mutant lacking aa 452–457 decreases TAB1-dependent phosphorylation of p38 MAPK. It also enhances
TAB1-dependent CCL5 secretion in response to IL-1 and increases activity of a post-transcriptional reporter gene, which
contains the CCL5 39 untranslated region. These data suggest a complex role of aa 452–457 of TAB1 in controlling p38 MAPK
activity and subcellular localization and implicate these residues in TAK1- or p38 MAPK-dependent post-transcriptional
control of gene expression.
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Introduction
A complex interplay of protein kinases and their phosphorylated
substrates regulates major aspects of immune and stress responses
[1]. One of these kinases is TGFb-activated protein kinase (TAK)-
1 which is activated by proinflammatory cytokines (IL-1, TNF, IL-
18), pathogens, RANKL, stresses and during T- and B-cell
activation and thus represents a prototypic central effector acting
upstream of NF-kB, JNK and p38 MAPK signaling pathways
[2–6].
TAK1 activation is tightly controlled by reversible phosphor-
ylations, non-degradative ubiquitination and by protein:protein
interactions. The latter include interactions with TAK1-binding
proteins (TAB) 1–3 which all have been shown to participate in
TAK1 activation. Hence, TAB1–3 can be viewed as crucial
regulatory subunits of the active TAK1 kinase complex [7–12]. In
TAB2 and TAB3, C-terminal Zn-finger motifs provide a docking
surface for K63-linked ubiquitin chains which are conjugated by
E3-ligases such as TRAF6 or TRAF2 to various signaling
intermediates after activation by innate immune receptors. These
covalently attached ubiquitin-chains recruit TAK1 in complex
with TAB2 or TAB3 to IL-1, TNF or TLR receptors [13,14].
The TAB1 subunit is also present in TAK1/TAB2-polyubiqui-
nated immunoprecipitated protein complexes after IL-1 stimula-
tion [8,15]. However, unlike TAB2 or TAB3 it apparently does
not serve to direct TAK1 to receptors of the immune response
[10]. Instead, a regulatory domain contained in amino acids 437–
504 of TAB1 binds to TAK1 and is fully sufficient to activate
ectopically expressed TAK1 suggesting that the primary role of
TAB1 is the regulation of TAK1 catalytic activity [16–19].
In addition to TAK1, TAB1 interacts with p38 MAPK and
activates its autophosphorylation by an allosteric mechanism.
TAB1-mediated p38 MAPK autoactivation occurs independent
from all three p38 MAPK-activating kinases (MKK3, MKK6,
MKK4) but accounts for only a small portion of overall p38
MAPK activity in a cell-and stimulus-dependent manner [20–24].
As illustrated in the upper panel of Fig. 1A, three functional
domains in TAB1 have been defined resembling the aforemen-
tioned TAK1 C-terminal activation domain [16,17], a p38 MAPK
interaction domain [22,24] and a pseudophosphatase domain [25].
By mass spectrometry and by phospho-site specific antibodies,
TAB1 was shown to be phosphorylated at S423, T431 and S438 by
ERK1, p38 MAPK or JNK [20,26]. Inhibition of these kinases
[20,26]orectopicexpressionofa dominant negativeTAB1 ST423/
431AA mutant [6] revealed a role of these residues in controlling
TAK1 enzymatic activity by a negative feedback mechanism that
inhibits TAK1-activation [6,20,26]. In addition, inactivation of
TAK1 can result from dephosphorylation by the serine/threonine
phosphatasesPP2C,PP6andcalcineurin[27–29]orfrominhibition
by bacterial virulence factors such as YopP [15]. All these
observations point to a complex but only partially understood array
of regulatory mechanisms that shapes the functions of the TAB1–3
proteins in the TAK1 and p38 MAPK pathways.
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While ablation in mice or RNAi-mediated suppression of TAB1
has no effect on IL-1-, TNF-, or TLR-induced activation of NF-
kB, JNK, or p38 MAPK signaling pathways, suppression of TAK1
abolishes these signals [2,3,6,26,30–33]. A recent report using
reconstituted TAB1-deficient fibroblasts suggested that TAB1
functions specifically in osmotic stress-induced TAK1 and
subsequent JNK activation providing first evidence for a highly
selective function of TAB1 in TAK1-signaling [34].
In previous experiments aimed at investigating the effects of
activated p38 MAPK or TAK1 on TAB1 we have described three
different posttranslationally modified forms of TAB1 that can be
distinguished based on mobility shifts upon SDS-PAGE [15].
Here, we report the identification of novel TAK1- and p38
MAPK-mediated phosphorylation sites underlying these shifts. We
also present evidence suggesting that the serine cluster containing
these phosphorylation sites in TAB1 is involved in regulation of
TAB1 and p38 MAPK subcellular localization and affects post-
transcriptional gene expression.
Results
Identification of novel phosphorylation sites in TAB1 at
amino acids 452/453 and 456/457
In addition to the already described S423, T431 and S438
residues, the C-terminal part of TAB1 contains several conserved
serine/threonine residues which may also be subject to regulatory
phosphorylations (Fig. 1A, lower panel). Initial experiments using
mutated TAB1 versions revealed that the major TAK1- or p38
MAPK-inducible shifts of TAB1 occurred independent of S423/
T431/S438 (Fig. S1A). As exemplified for S425, individual
mutation of some of the other conserved sites in the C-terminal
part of TAB1 had no effects on TAB1 mobility shifts (Fig. S1B,
compare lanes 5–8 with lanes 1–4).
In contrast, deletion of six serines comprising aa 452–457
(TAB1DS) abolished TAB1 form 1 in response to both, overex-
pressed MKK62E/p38 MAPK (Fig. 1B, lane 7) or overexpressed
TAB1/TAK1 (Fig. 1B, lane 8) despite normal phosphorylation of
S438 as assessed by a phospho-specific antibody (Fig. 1B). Of note,
Figure 1. Identification of new phosphorylation sites in TAB1. A) Upper panel: schematic structure of TAB1 indicating functional domains and
known phosphorylation sites (S423, T431, S438) as well as the new sites described in this study (SS452/453, SS456/457). Lower panel: alignment of
part of the TAK1 activation domain of TAB1. Conserved potential phosphorylation sites are indicated by asterisks, phospho amino acids analyzed in
this study are shaded gray. B)–D) HEK293IL-1R cells were transiently transfected with expression vectors for HA-TAB1 wild type or versions in which
S438 was mutated to alanine and/or aa 452–457 were deleted (TAB1DS) alone or in combination with GFP-YopP, FLAG-p38 MAPK plus MKK62E or
HA-TAK1 as indicated. 24 h later cells were lysed followed by immunoblotting (IB) to detect HA-TAK1, FLAG-p38 MAPK or HA-TAB1 antigens and the
phosphorylated forms of TAB1 using the indicated antibodies. Equal loading of lanes was confirmed using anti ß-actin antibodies. Black arrowheads
indicate the three forms of TAB1 (numbered 1–3) with different mobility upon SDS-PAGE as previously described by us [15].
doi:10.1371/journal.pone.0029256.g001
Novel Phosphorylation Sites in TAB1
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29256under these activated conditions, the deletion mutant TAB1DS
migrated faster and mainly occurred as mobility form 2 (Fig. 1B,
lanes7,8).Aspreviouslypublishedbyourgroup[15],YopP(Fig.1B,
lane 6) shifted TAB1DS further downwards to form 3 which is
explained by YopP affecting both, phosphorylation of aa 452–457 as
well as the previously characterized p38 MAPK site S438.
In order to identify which of the six serines were phosphory-
lated, we generated phospho-specific antibodies against di-
phosphorylated peptides containing either SS452/453 or SS456/
457. A careful mutational analysis revealed the specificity of these
antibodies for their respective residues (Fig. S2). As shown in
Fig. 1B–D, both, activated p38 MAPK and TAK1 induced the
phosphorylation at SS452/453 and SS456/457, an effect which
was abolished by deleting the serine cluster of aa 452–457 in the
TAB1DS variant (Fig. 1B). Moreover, phosphorylation at SS452/
453 or SS456/457 under these conditions was independent from
mutation of the p38 MAPK site S438 (Fig. 1C). However,
mutation of both, S438 and aa 452–457 abolished all major TAB1
shifts suggesting that these amino acids are the prevalent sites of
TAB1 modifications in intact cells (Fig. 1D).
Using immunopurified active p38 MAPK we also found that
p38 phosphorylates recombinant GST-TAB1 (Fig. 2A, B) but not
a GST-TAB1 SSSS452/453/456/457AAAA mutant in vitro with a
kinetic similar to that of the already known p38 MAPK site S438
(Fig. 2B). A similar result was obtained for activated TAK1
(Fig. 2C). These assays further established the specificity of the
phospho-specific antibodies and revealed SS452/453 and SS456/
457 as direct novel target sites for both, p38 MAPK and TAK1.
Phosphorylation of TAB1 at amino acids 452–457 is
regulated by stress stimuli and cytokines
We then tried to identify the stimuli which regulate SS452/453
and SS456/457 phosphorylation. It has been previously noticed
that activation of TAK1 by proinflammatory cytokines such as IL-1
is transient, because it’s catalytic activity is rapidly downregulated
by serine/threonine phosphatases such as PP6 [28], PP2C isoforms
[27,35,36] or calcineurin [29]. In line with the dependency of
activation of the TAK1 complex on reversible phosphorylation, the
strongest condition that induced phosphorylation of TAB1 at
SS452/453 or SS456/457 was treatment of cells with the
phosphatase inhibitor calyculin A (Fig. 3A, lane 1). SS452/453
werealso phosphorylatedinresponsetoIL-1,anisomycinorsorbitol
treatment, whereas detectable SS456/457 phosphorylation was
only observed with anisomycin or sorbitol (Fig. 3A). In these
experiments intracellular TAB1 levels were increased by overex-
pression of MYC-TAB1 to increase sensitivity of detection. All
conditions shown in Fig. 3A also activated p38 MAPK to varying
degrees which correlated with the level of TAB1 phosphorylation.
We also found that phosphorylation of endogenous TAB1 at
SS452/453 could be detected by immunoprecipitating TAB1 from
sorbitol-stimulated cells. This effect was suppressed by the TAK1
inhibitor 5Z-7-oxozeaenol confirming that these sites are regulated
by a TAK1-dependent pathway in (patho)physiological settings
(Fig. 3B). However, phosphorylation of endogenous TAB1 was
only measureable when low concentrations of phosphatase
inhibitors were added to the cells prior to cell lysis and by using
the strongest TAK1 stimulus sorbitol suggesting that phosphory-
lation of TAB1 at aa 452–457 is very low abundant.
Amino acids 452–457 of TAB1 are not involved in TAK1
activation
Since the best defined function of TAB1 is the activation of
TAK1 in a co-expression system, we transiently co-transfected
wild type TAB1 or the TAB1DS mutant together with TAK1. As
shown in Fig. S3, in HEK293IL-1R cells, TAB1DS had no effect
on in vitro kinase activity of immunoprecipitated TAK1:TAB1
complexes (Fig. S3A) and only very little effect on TAK1:TAB1
activation of IL-8 transcription (Fig. S3B), a gene whose expression
is controlled by the TAK1 pathway [11]. Stable reconstitution of
MYC-TAB1 in TAB1-deficient mouse embryonic fibroblasts
partially restored in vitro kinase activity of immunoprecipitated
TAK1 complex in response to calyculin A treatment compared to
wild type cells (Fig. S3C). However, this effect was not influenced
by reintroducing the S423, T431, S438 or the DS mutants in the
TAB1-deficient background (Fig. S3C). We also tested if aa 452–
457 were involved in ubiquitination of TAK1 and of TAB1 itself
under conditions previously described by us [15]. However,
deletion of aa 452–457 did not affect ubiquitination of either
TAK1 or TAB1 (Fig. S3D). Collectively, these data suggested that
aa 452–457 did not disturb correct folding of the minimal TAK1-
activation domain comprising amino acids 480–504 [17] and did
not play a role in TAK1 activation.
An active mutant of p38 MAPK phosphorylates TAB1 at
aa 452/453 in the cytoplasm
We, therefore, tested a potential role of aa 452–457 in activation
and localization of p38 MAPK based on reports of a direct
interaction between p38 MAPK with TAB1 [20–22,24,37].
In contrast to Ge et al. [24] we were unable to activate p38
MAPK with TAB1 in vitro precluding an analysis of aa 452–457
on the in vitro kinase activity of p38 MAPK (data not shown).
Therefore, we tested if TAB1 was able to affect phosphorylation
of p38 MAPK in intact cells. Both, TAB1 and p38 MAPK were
co-expressed and the phosphorylation state of p38 MAPK was
investigated by immunoblot analysis of whole cell lysates
( F i g .4 A ) .I na g r e e m e n tw i t hG eet al. [24] we found that
overexpression of TAB1 increased phosphorylation of p38
MAPK. In our experiments, this occurred primarily at T180
but also at Y182 in intact cells (Fig. 4A, lane 3). This effect was
reduced by co-expressing TAB1DS, providing support for a
TAB1-dependent activation mechanism of p38 MAPK that
involves aa 452–457 (Fig. 4A, lane 4). We also tried to test the
localization of TAB1 and p38 MAPK under conditions which
induce strong TAB1 phosphorylation at SS452/453 or SS456/
457. However, stress-related rounding up and detachment of
cells under conditions of transfection of MKK62E or TAB1/
TAK1, or, calyculin A or sorbitol treatment prevented
microscopic analysis of TAB1 and p38 MAPK localization
(data not shown) under the conditions established in the
experiments shown in Fig. 1 and Fig. 3.
We, therefore, designed experiments to activate p38 MAPK by
a separate strategy. Specifically, we used a p38 MAPK Y182F
mutant which was shown by [38] to gain some kinase activity in
vitro albeit to a much lower level than p38 MAPK fully
phosphorylated at T180 and Y182 [38]. We applied this mutant
of p38 MAPK to mimic modest activation of this pathway in the
absence of any upstream trigger for analyzing p38 MAPK-
specific effects on TAB1. Overexpression of wild type forms of
p38 MAPK and TAB1 together resulted in increased phosphor-
ylation of p38 MAPK as expected from the results shown in
Fig. 4A. However, under this condition there was also increased
phosphorylation of TAB1 at SS425/453 and SS456/457 (Fig. 4B,
lane 2). The gain-of-function mutant p38 MAPK Y182F
stimulated its own catalytic activity as assessed by increased
autophosphorylation at T180 (Fig. 4B, lane 4). Moreover, when
TAB1 was co-expressed with p38 MAPK Y182F, phosphoryla-
tion at both, SS452/453 and SS456/457 of TAB1 increased
Novel Phosphorylation Sites in TAB1
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phosphorylate these residues in intact cells (Fig. 4B, lane 4).
Compared to co-expression of wild type p38 MAPK plus TAB1,
co-expression of the active p38 MAPK Y182F mutant resulted in
a primarily cytosolic localization of MYC-tagged TAB1 (Fig. 4C,
columns 2 and 3). Moreover, p38 MAPK Y182F significantly
increased TAB1 phosphorylation in the cytoplasm (Fig. 4C,
column 3). This result suggests that phosphorylation of aa 452–
457 of TAB1 is a means to promote cytosolic localization of
TAB1. Collectively, the results shown in Fig. 4A to Fig. 4C
suggest that aa 452–457 are engaged in TAB1-dependent
activation of p38 MAPK but are also direct targets of p38
MAPK as schematically shown in Fig. 4D.
Deletion of amino acids 452–457 and phospho-mimetic
mutants of TAB1 target TAB1 and p38 MAPK to the
cytoplasm
To further reveal the role of aa 452–457 in p38 MAPK
signaling, we analyzed the effects of deletion (TAB1DS), and
phosphomimetic (TAB1 4SE) or phosphorylation-deficient (TAB1
4SA) mutants on both, p38 MAPK and TAB1 localization. In
agreement with [39] we found in HEK293IL-1R cells that the
majority of FLAG-p38 MAPK is localized in the nucleus of
transfected cells (Fig. 5B, 2
nd column). This effect is not changed
by co-expressed wild type MYC-TAB1 (Fig. 5B, 3
rd column).
However, co-expression of TAB1DS or TAB1 4SE but not of a
TAB1 4SA mutant resulted in an almost complete cytosolic re-
Figure 2. Active p38 MAPK and TAK1 phosphorylate SS452/453 and SS456/457 of TAB1 in vitro. A, B) HEK293IL-1R cells were transiently
transfected with expression vectors for FLAG-p38 MAPK, inactive FLAG-p38 MAPK (T180A/Y182F, AF) or MKK62E as indicated. In C) cells were
transfected with HA-TAK1, or inactive HA-TAK1 K63W plus MYC-TAB1 in the indicated combinations. 24 h later cells were lysed and used to isolate
activated p38 MAPK (A, B) or TAK1 (C) by immunoprecipitation (IP). Activated p38 MAPK or TAK1 were incubated with recombinant GST-TAB1 and
ATP as substrates. After 30 min, in vitro kinase reactions were terminated by separating GST-TAB1 with GSH-sepharose (A, C). Phosphorylation of GST-
TAB1 in vitro was analyzed by immunoblotting using phospho-SS452/453, phospho-SS456/457 and phospho S438 specific antibodies. B) A similar
experiment as in A) was performed using a GST-TAB1 SSSS452/453/456/457AAAA (GST-TAB1 4SA) mutant in parallel. The assay also demonstrates the
kinetic of aa 452–457 phosphorylation by p38 MAPK in vitro. Equal immunopurification of kinases and of recovery of GST-TAB1 was validated by
immunoblotting of lysates, immunoprecipitates or GST-TAB1 purified from reaction mixtures by the indicated antibodies. Comparable amounts of
inactive p38 MAPK (AF) and TAK1 (K63W) were used in parallel to demonstrate the specificity of the kinase reactions.
doi:10.1371/journal.pone.0029256.g002
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th to 6
th
column). These results suggested that the serine cluster or its
phosphorylation regulate cytosolic retention of TAB1 and of p38
MAPK.
Collectively, the results shown in Fig. 4 and 5 indicate that p38
and TAB1 mutually control their subcellular localization and
imply that aa 452–457 are involved in interactions of phospho-
TAB1 and active p38 MAPK to control the cytoplasmic pool of
both proteins.
Amino acids 452–457 of TAB1 play a role in post-
transcriptional gene regulation
In order to assign additional biological functions to aa 452–457
of TAB1 we used stably reconstituted TAB1-deficient Mefs
infected with retroviral expression vectors containing either
untagged (Fig. 6A) or MYC-tagged (Fig. 6B) versions of TAB1
or TAB1DS. In line with previous studies [30,33,34,40] we did not
observe significant changes of IL-1-induced NF-kB, JNK and p38
MAPK pathways in TAB1-deficient Mefs (data not shown). As the
data presented in Fig. 4 and Fig. 5 pointed to a cytosolic function
of aa 452–457 of TAB1, and TAB1 siRNA were found to effect
secretion of IL-8, IL-6, MCP-1 and GM-CSF in IL-1-treated
HeLa cells [40] we screened the supernatants of TAB1-deficient
and of reconstituted cells for secreted cytokines by antibody arrays.
As shown in Fig. 6C, IL-1-induced CCL5 secretion was impaired
in the absence of TAB1 and was restored upon reconstitution.
Other IL1-induced genes such as G-CSF were unaffected by
ablation of TAB1 suggesting a specific role of TAB1 in the IL-1
response. Compared to wild type TAB1, the IL-1-induced
secretion of CCL5 was enhanced by approximately 30% by
reconstituting cells with either untagged, or MYC-tagged versions
of TAB1DS as assessed by specific ELISA (Fig. 6D).
Further experiments were performed to assess at which step of
gene regulation TAB1DS affected CCL5 expression. As TAB1-
deficient Mefs were difficult to transfect transiently we analyzed
A549 cells which strongly upregulate CCL5 protein and mRNA in
response to IL-1 in a TAK1-dependet manner (Fig. S4). A
previously described CCL5 promoter reporter gene construct [41]
did not reveal any regulation by IL-1 and showed an inhibition of
basal promoter activity upon co-expression of TAB1 wild type or
TAB1DS (data not shown). We, therefore, fused the entire 39
untranslated region (UTR) of the CCL5 mRNA to a luciferase
cDNA (Fig. 7A) to investigate post-transcriptional regulation of
CCL5. Fusion of the CCL5 39 UTR decreased luciferase mRNA
and activity by 2–3-fold in reporter gene assays suggesting that the
CCL5 39 UTR conferred mRNA destabilization to the otherwise
stable luciferase mRNA (Fig. 7B). Co-transfection of TAB1 did not
alter this destabilizing effect, whereas co-transfection of TAB1DS
increased steady state levels of the mRNA by 2.5-fold and
luciferase activity by about 1.5-fold in seven independent
transfection experiments (Fig. 7C). Together with the mainly
cytosolic localization of the TAB1DS and TAB1 4SE mutants as
Figure 3. Phosphorylation of TAB1 at SS452/453 or SS456/457 in response to IL-1 or stress-stimuli. A) HEK293IL-1R cells were transiently
transfected with an expression vector for MYC-TAB1. 24 h later, cells were treated with 40 nM calyculin A, 10 ng/ml IL-1a,1 0mg/ml anisomycin or
0.5 M sorbitol for the indicated times or were left untreated. Lysates were subjected to immunoblotting (IB) to detect phosphorylation of TAB1 using
phospho-SS452/453-TAB1 or phospho-SS456/457-TAB1-specific antibodies. Phosphorylation of p38 MAPK at T180/Y182 and of TAK1 at T187 and
equal loading of MYC-TAB1, TAK1 and p38 MAPK were analyzed using the indicated antibodies. B) HEK293IL-1R cells were treated for 30 min with
10 nM calyculin A in all samples and with the TAK1 inhibitor 5Z-7-oxozeaenol (1 mM) as indicated followed by sorbitol (0.5 M) for 30 min, by sorbitol
alone or were left untreated. Thereafter, cells were lysed, proteins were immunoprecipitated with anti-TAB1 or control (IgG) antibodies and TAB1 or
phospho-TAB1 were detected by the indicated antibodies.
doi:10.1371/journal.pone.0029256.g003
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post-transcriptional control of cytokine-responsive mRNAs such
CCL5.
Discussion
TAB1 was the first TAK1-binding protein to be discovered [7].
TAB1 has also been implicated in an alternative allosteric
activation mechanism of p38 MAPK [24]. Moreover, the protein
is modified at multiple residues [20,26]. Despite these findings, as
outlined above the biological role of TAB1 in the TAK1-MKK3/
6-p38 MAPK pathways or in any other biological process is not
well understood.
Here, we add more facets to this apparent complexity of TAB1
regulation by identifying the serine cluster surrounding aa 452–
457 as new phosphorylation sites and as a new functional domain
within TAB1. These sites were detected by conventional
biochemical approaches and were confirmed using phospho-
specific antibodies. Importantly, none of these sites were
discovered by previous mass spectrometry approaches [20,42,43]
underscoring that a combination of different techniques is required
to reveal all possible modifications in TAB1.
TAK1 and p38 MAPK phosphorylated TAB1 at SS452/453
and SS456/457 in vitro and in intact cells. Physiological
phosphorylation at these sites was vey difficult to detect, but the
available evidence suggests that a broader range of known TAK1-
Figure 4. Amino acids 452–457 of TAB1 promote p38 MAPK phosphorylation and p38 promotes phosphorylation of TAB1. (A)
HEK293IL-1R cells were transiently transfected with empty vector, or FLAG-p38 MAPK alone or in combination with MYC-TAB1 wild type (wt) or MYC-
TAB1 lacking aa 452–457 (DS). After 48 h, aliquots of lysates were analyzed by IB for phosphorylation of p38 MAPK at T180/Y182 or at T180 and for
expression of the transfected proteins using MYC or FLAG antibodies. (B) HEK293IL-1R cells were transiently transfected with expression vectors for
HA-TAB1, FLAG-p38 MAPK wild type (wt) or versions with T180A (TA) or Y182F (YF) mutations as indicated. After 24 h aliquots of lysates were
analyzed by IB for phosphorylation of TAB1 at SS452/453 and SS456/457, p38 MAPK at T180/Y182 or T180 and for expression of the transfected
proteins using the indicated antibodies. C) HEK293IL-1R cells were transiently transfected with empty vector or expression vectors encoding MYC-
TAB1 or FLAG-p38 MAPK wild type (wt) or the p38 MAPK Y182F (YF) mutation as indicated. After 24 h, cells were seeded for 24 h in m-slides followed
by double-immunofluorescence microscopy using anti MYC (green color) or anti phospho-TAB1 (red color) antibodies to detect TAB1 localization and
phosphorylation at SS452/453. In IF-control, the primary antibodies were omitted. Nuclei were visualized by Hoechst staining (blue). Scale bar is
10 mM. Numbers indicate percentage of transfected cells with the respective phenotype. D) Scheme indicating mutual control of TAB1 and p38 MAPK
involving aa 452–457.
doi:10.1371/journal.pone.0029256.g004
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stressors targets these sites. Moreover, the strongest inducing
condition was either overexpressing active TAK1 or p38 MAPK
or blocking serine/threonine phosphatases by calyculin A implying
that SS452/453 and SS456/457 are tightly controlled by
reversible phosphorylation events. As we did not find a significant
contribution of aa 452–457 to activation of TAK1, we focused on
a putative role in p38 MAPK functions.
Experiments in transfected cells suggest that aa 452–457 played
a role in cytosolic retention of both p38 MAPK and TAB1.
Overexpressed p38 MAPK and its phosphorylated form is known
to reside in the nucleus [39]. However, p38 MAPK localization is
Figure 5. Mutations of aa 452–457 direct p38 MAPK and TAB1 to the cytoplasm. HEK293IL-1R cells were transiently transfected with empty
vector or expression vectors for FLAG-p38 MAPK alone or in combination with MYC-TAB1 wild type (wt), MYC-TAB1 lacking aa 452–457 (DS), MYC-
TAB1 SSSS452/453/456/457EEEE (MYC-TAB1 4SE), or MYC-TAB1 4SA. After 24 h, cells were seeded for 24 h in m-slides followed by double-
immunofluorescence microscopy using anti FLAG and anti TAB1 (H-300) antibodies to detect intracellular localization of p38 MAPK (1
st row, red) or
TAB1 (2
nd row, green) by single or merged images (3
rd row). In IF-control, the primary antibodies were omitted. Nuclei were visualized by Hoechst
staining (blue). Scale bar is 10 mM. Numbers indicate percentage of transfected cells with the respective phenotype.
doi:10.1371/journal.pone.0029256.g005
Figure 6. Amino acids 452–457 participate in modulation of TAB1-dependent CCL5 chemokine secretion in the IL-1 pathway. Murine
embryonic fibroblasts were stably infected with retroviruses encoding untagged (A) or MYC-tagged (B) TAB1 wild type (wt) or TAB1 lacking aa 452–
547 (DS). Lysates from pools of cells were analyzed for expression of the TAB1 and p38 MAPK proteins using the indicated antibodies. C) Cells from (A)
were stimulated for 24 h with IL-1a (10 ng/ml) or were left untreated. Supernatants were analyzed for secretion of cytokines by antibody arrays.
Results show images of raw data obtained for two IL-1-regulated proteins (CCL5, G-CSF), one unregulated but secreted protein (M-CSF) and a positive
control. D) Supernatants of cells from (A) or (B) were treated as in C) and analyzed for CCL5 secretion by ELISA. Data were normalized for protein
content of cell pellets harvested in parallel. Shown are the mean ratios +/2 S.E.M. of IL-1-regulated CCL5 secretion from two independent
experiments.
doi:10.1371/journal.pone.0029256.g006
Novel Phosphorylation Sites in TAB1
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e29256highly dynamic, as p38 MAPK redistributes to the cytoplasm upon
stress via the nuclear export signal of its substrate and interaction
partner MK2 [39,44]. Both studies showed that the trafficking of
p38 MAPK is determined by the stoichiometry of p38
MAPK:MK2 complexes [39,44]. Another study showed in rat
cardiomyocytes that p38a MAPK travels not only with MK2 but
also together with TAB1. Thus, TAB1 versions fused to either a
cytosolically located red fluorescent protein (RFP-TAB1) or to a
nuclear localization signal (NLS-TAB1) directed a GFP-p38
MAPK fusion protein towards the cytoplasm or the nucleus,
respectively [37]. Our data strengthening this concept and suggest
that the serine cluster of aa 452–457 is involved in nuclear
targeting, as its deletion promotes a primarily cytosolic localization
of TAB1 and of p38 MAPK (Fig. 5). Interestingly, the
phosphomimetic mutant TAB1 4SE has the same phenotype,
whereas the TAB1 4SA mutant promotes nuclear localization
suggesting that in the natural TAB1 protein phosphorylation of
the serine rich cluster targets TAB1 and p38 MAPK to the
cytoplasm. A mechanistic explanation might be that TAB1
through aa 452–457 binds to an unknown nuclear partner
protein. This interaction is relieved upon phosphorylation at aa
452–457. Released TAB1 then redistributes to the cytoplasm
carrying p38 MAPK with it. In this model, lack of aa 452–457
would impair binding, whereas prevention of phosphorylation as
shown by the TAB1 4SA mutant would stabilize binding to the
speculative nuclear partner protein of TAB1, explaining the
cytoplasmic versus nuclear localization of TAB1 DS and TAB1
4SA as shown in Fig. 5, respectively.
Only three partial 3-D structures of TAB1 are available, derived
from crystals of either N-terminal fragments of aa 7–402 [25] or aa
1–370 [45] or from a crystal structure of a fusion protein of aa
468–504 fused to the TAK1 catalytic domain (aa 31–303) [46].
The serine cluster described in our study is not part of these
structures and is also not involved in p38 MAPK binding [22]. It
does neither resemble a classical basic nuclear localization signal
(NLS) [47] nor a nuclear translocation signal (NTS) [48]. Hence, it
apparently represents a novel regulatory domain in TAB1 which
participates in fine-tuning of the p38 MAPK signaling pathway by
contributing to p38 MAPK localization and autoactivation of the
kinase independent from the classical MAP3K-MAP2K-MAP
kinase cascades.
We also tried to validate a role of aa 452–457 in regulating p38
MAPK:TAB1 interactions by co-immunoprecipitation. However,
there was little if any stable interaction of p38 MAPK with TAB1
in these assays (data not shown). This would suggest that the
protein:protein interaction is either very labile or indirect.
However, TAB1 promoted p38 MAPK phosphorylation primarily
at T180 and the gain-of-function mutant of p38 MAPK Y182F
promoted TAB1 phosphorylation at aa 452–457 adding further
evidence for a mutual control of both proteins (Fig. 4).
The results presented in this study can be reconciled by the
following model: in unstimulated cells, a low level of p38 MAPK
activity is observed that is caused by a TAB1-dependent activation
mechanism involving p38 MAPK auto-phosphorylation at T180.
Conversely, TAB1 can be phosphorylated by p38 MAPK at
serines 452–457 (Fig. 1, 2, 4) retaining the phosphorylated protein
Figure 7. Amino acids 452–457 of TAB1 participate in mRNA-destabilization mediated by the CCL5 39 untranslated region. A) Scheme
of the luciferase encoding empty control vector and the construct harboring the CCL5 39 UTR. B) A549 cells were transiently transfected with the
control vector or the version carrying the CCL5 39UTR together with SV-40-ß-gal. After 24 h, cells were splitted into two halves, one of which was used
to extract total RNA and the other was lysed for determination of luciferase activity. Luciferase mRNA was measured by RT-qPCR and luciferase
activity was assessed using a chemiluminescence assay and normalized for ß-galactosidase activity. Depicted is the relative mRNA expression and
luciferase activity in the presence or absence of the CCL5 39UTR. Data are shown as mean values +/2 s.e.m. which were determined in 13
independent transfection experiments. C) Similar experiments as in B) were performed including co-expression of MYC-TAB1 wild type or MYC-
TAB1DS. Shown is the mean ratio +/2 s.e.m. of luciferase mRNA expression or activity as determined in at least seven independent transfection
experiments. An increased ratio value indicates a reduced destabilizing effect of the CCL5 39UTR relative to empty vector control. Lysates from
transfected cells were analyzed for expression of TAB1 proteins using the indicated antibodies. Equal loading of lanes was confirmed using anti
tubulin antibodies.
doi:10.1371/journal.pone.0029256.g007
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kept unphosphorylated by serine/threonine phosphatases and is
found in the nucleus. Accordingly, we identified three conditions
that shift this balance towards strong phosphorylation at aa 452–
457 of TAB1: (i) blockade of phosphatases by calyculin A (Fig. 3),
(ii) strong osmotic or translational stress (Fig. 3) and (iii) ectopic
expression of TAK1, p38 MAPK plus MKK62E or the gain-of-
function mutant p38 MAPK Y182F together with TAB1 (Fig. 1, 2,
4). Both, TAB1 versions lacking aa 452–457 or carrying phospho-
mimetic mutations trapped p38 MAPK in the cytoplasm (Fig. 5).
This suggests that phosphorylated TAB1 may support post-
transcriptional functions of p38 MAPK such as regulation of CCL5
mRNA stability (Fig. 7) and secretion (Fig. 6).
Although TAK1 is another kinase that phosphorylates aa 452–
457, we did not find any general effects of TAB1 mutants on
overall TAK1 activation in the settings analyzed in this study.
Therefore, TAB1 molecules phosphorylated at aa 452–457 by
TAK1 may have unknown roles in stimulus-specific activation of
TAK1 pathways.
In summary, our study suggests an intimate mutual control of
p38 MAPK and its allosteric activator TAB1. Both proteins
control dynamically each other’s phosphorylation status, activity
and subcellular localization. Our results further establish TAB1 as
a multi-site phosphorylated protein and provide another piece in
the puzzle of solving the function of the ‘‘enigmatic’’ TAB1.
In depth clarification of the underlying mechanisms will require
much more extensive studies for identifying TAB1-interacting
molecules that are controlled by phosphorylation of aa 452–457
and that are involved in TAB1-dependent biological functions.
Materials and Methods
Cells and materials
HEK293 cells stably expressing the IL-1 receptor (HEK293IL-
1R) [15], TAB1 2/2 murine embryonic fibroblast lines, a kind
gift of Kunihiro Matsumoto [33], and A549 lung epithelial
carcinoma cells (catalogue number ACC 107, obtained from
DSMZ, German Collection of Microorganisms and Cell Cultures)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM),
complemented with 10% fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin. Antibodies against
the following proteins or peptides were used: actin (JLA20; EMD)
and TAK1 (M-579, sc-7162), TAB1 (H-300, sc-13956), GST (Z-5,
sc-459), tubulin (TU-02, sc-8035), TAB2 (K-20, sc-11851), rabbit
IgG (sc-2027) all from Santa Cruz, MYC (9E10), HA (12CA5),
GFP (clone 7.1 and 13.1) all from Roche, FLAG M2 (F1804,
Sigma), P(T180/Y182)-p38 MAPK (36–850, Invitrogen), P(T180)-
p38 MAPK (02504), P(S438)-TAB1 (09519) both from Acris,
TAK1 (4505), P(T187)-TAK1 (4536), TAB1 (C25E9) all from Cell
signaling. p38 MAPK [49] and P(T187)-TAK1 [6]. Purified
polyclonal antibodies that recognize specific phosphorylation
sites in human TAB1 were raised by Eurogentec against the
following peptides: TNTHTQpSpSSSSSD (SS452/3) and
TQSSSSpSpSDGGLF (SS456/7), where pS denotes a phosphor-
ylated serine.
Plasmids, transfections, reporter gene assays, RT-qPCR
The expression vectors pCMV-FLAG-p38 MAPK, pCDNA3-
MKK62E [50,51], pCMV-HA-TAK1, pCMV-HA-TAK1K63W,
pUHC13-3-IL-8 promotor, pSV40-ß-Galactosidase [11],
pCDNA3-GFP-YopP, pCDNA3-GFP-TAK1, pCS2MT-MYC-
TAB1, pCDNA3-HA-TAB1, pCDNA3-HA-TAB1 S438A,
pCDNA3-HA-TAB1 S423/T431AA (STS/AAS), pCDNA3-HA-
TAB1 S423/T431/S438AAA (STS/AAA), pDEST26-HIS-Ubiq-
uitin [15] and pGEX-GST-TAB1 [17] have been described. The
following plasmids were constructed by standard cloning tech-
niques: pCDNA3-HA-TAB1 lacking aa 452–457 (DS), pCDNA3-
HA-TAB1 S438A DS, pCDNA3-HA-TAB1 S425A, pCDNA3-
HA-TAB1 S452A, pCDNA3-HA-TAB1 S453A, pCDNA3-HA-
TAB1 S456A, pCDNA3-HA-TAB1 S457A, pCDNA3-HA-TAB1
S452E, pCDNA3-HA-TAB1 S453E, pCDNA3-HA-TAB1
S456E, pCDNA3-HA-TAB1 S457E, pCS2MT-MYC-TAB1 DS,
pCS2MT-MYC-TAB1 S452/3/6/7A (4SA), pCS2MT-MYC-
TAB1 S452/3/6/7E (4SE), pGEX-GST-TAB1 4SA, pCMV-
FLAG-p38 T180A (TA), pCMV-FLAG-p38 Y182F (YF), pCMV-
FLAG-p38 T180/Y182AF (AF). Mutations were performed using
the Stratagene site directed mutagenesis kit, a modification of
which [52] was also used for deletion of the region encoding aa
452–457 in TAB1. pSGG-luciferase- CCL5 39UTR and pSGG-
luciferase-EMPTY (Fig. 7A) were purchased from switch gear
genomics.
For retroviral expression, a cDNA encoding TAB1 was amplified
from pCDNA3.1-HA-TAB1 [15] using the primers (se: 59-GCG-
CGAATTCAATGGCGGCGCAGAGG-39;a s : 5 9-GCGCCTCG-
AGTATCGATACTACGCTGCTGTCACCACG-39), cloned into
pCR-Blunt II-TOPO and then subcloned into the EcoRI and XhoI
sites of pCS2-MT. A ClaI fragment of pCS2-MT-MYC(6)-TAB1 was
then cloned into the ClaI site of pM5XNeo to generate pM5XNeo-
MYC-TAB1. pM5XNeo-TAB1 was generated by excising the
MYC-tags by EcoRI digestion and religation. Recombinant
retroviruses and infections of Mef cells were done exactly as described
in [49]. Stable cell lines were selected using 1 mg/ml G418.
Calcium phosphate transfections and reporter gene assays were
performed as described [53,54].
Lipofectamine transfections of A549 cells were performed
according to the manufacturer’s instructions (Invitrogen, Lipofec-
tamine LTX and PLUS reagents Cat. no. 15338). Specifically,
A549 cells were seeded at 5–6610
5 in 9,4 mm wells. 24 h later
cells were transfected in duplicates with 2.5 mg plasmid DNA
containing 0.4 mg pSV40-ß-galactosidase + 0.1 mg pSGG-lucifer-
ase- CCL5 39UTR or pSGG-luciferase-EMPTY in combination
with 2 mg empty vector control or pCS2MT-MYC-TAB1wt or
pCS2MT-MYC-TAB1DS) and 3 ml PLUS reagent and 3.75 ml
lipofectamine in DMEM per well. After 6 h at 37uC, 5% CO2, the
medium was complemented with 10% fetal calf serum, 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin. The
next day, cells were harvested and splitted into two halves one of
which was used to extract mRNA and the other was lysed for
determination of luciferase activity or equal expression of the
TAB1 constructs.
RT-qPCR was performed as described [54]. cDNAs were
amplified using assays on demand (Applied Biosystems) for CCL5
(Hs00171085_m1), ß-actin (Hs99999903_m1) and luciferase (se-
primer: 59-GCGCAGCTTGCAAGACTATAAG-39, as-primer:
59-TTGTCGATGAGAGTGCTCTTAGC-39, probe: 59-CTGG-
TGCCCACACTAT-39).
Cell lysis and immunoprecipitations
Unless stated otherwise, cells were lysed in cell lysis buffer
(50 mM TrisHCl, pH 7.5, 100 mM NaCl, 0,1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 50 mM NaF, 1 mM Microcystin, 1 mM
Na3VO4, 5 mM sodium pyrophosphate, 0,1% ß-mercaptoethanol
and a Roche protease inhibitor mix). HEK293IL-1R cells (Fig.
S3B) and A549 cells (Fig. 7) transfected for reporter gene assays
were lysed in ß-galactosidase lysis buffer as described [53].
For immunoprecipitation of p38 MAPK (Fig. 2A, 2B), cells were
lysed in (10 mM Tris, pH 7.05, 30 mM NaPPi, 50 mM NaCl, 1%
Triton X-100, 2 mM Na3VO4, 50 mM NaF, 20 mM ß-glycero-
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and 1 mM microcystin). p38 MAPK was immunoprecipitated from
1.5 mg cell extract protein in (16Tris-buffered saline (TBS), 1%
Triton X-100, 1 mM Na3VO4, 2 mM DTT, 50 mM NaF) using
rabbit polyclonal anti p38 MAPK antibodies [49] (Fig. 2A) or
FLAG antibodies (Fig. 2B) coupled to protein-G-Sepharose 4 Fast
Flow (GE Healthcare). Beads were washed twice in the same
buffer, once in washing buffer containing (50 mM Tris, pH 7.5,
10 mM MgAc, 0.1% ß-mercaptoethanol) and redissolved in 10 ml
of washing buffer for in vitro kinase assays.
For immunoprecipitation of TAK1-TAB1 (Fig. 2C) or GFP-
TAK1 (Fig. S3A), cell extracts were incubated with protein G
Sepharose 4 Fast Flow coupled to 1 mg of MYC (9E10) or to 1 mg
of GFP (clone 7.1 and 13.1) antibodies for 2–6 h, respectively, with
gentle rocking at 4uC. Beads were then washed two times with cell
lysis buffer plus 0,5 M NaCl and once with washing buffer. Beads
were redissolved in 10 ml washing buffer for in vitro kinase assay or
were splitted into two halves one of which was boiled for 5 min in
26 Roti-Load (Roth) before loading on 8% SDS-PAGE. The
other half was redissolved in 10 ml washing buffer for in vitro kinase
assay.
For immunoprecipitation of endogenous TAB1 (Fig. 3B) cells
were lysed in (50 mM HEPES, pH 7.4, 50 mM NaCl, 1% Tween
20, 2,5 mM EGTA, 1 mM EDTA, 1 mM NaF,10 mM ß-
glycerophosphate, 0,1 mM Na3VO4, 1 mM PMSF, Roche
protease inhibitor mix, 1 mM DTT, 1 mM microcystin), sonified
3620 seconds on ice and centrifuged at 100.0006g for 20 min at
4uC. 1.5 mg of the supernatant was used for IP with 1.5 mg of anti
TAB1 (H-300) or IgG (sc-2027) antibodies coupled for 1 h to 15 ml
of Trueblot anti-mouse Ig immunoprecipitation beads (e-biosci-
ence, 00-8811-25). After 2 h, beads were washed three times in the
lysis buffer including 450 mM NaCl. Proteins were eluted by
boiling in 26Roti-Load before loading on SDS-PAGE.
Immunoprecipitation of the endogenous TAK1-TAB1-TAB2
complex (Fig. S3C) using TAB2 (K-20, Santa Cruz) antibodies
followed by in vitro kinase assay to measure TAK1 kinase activity
using recombinant HIS(6)-MKK6 and c[
32P]ATP as substrates
was performed as described [15].
In vitro kinase assays
Unless stated otherwise, in vitro kinase assays were carried out at
37uC for 30 min with agitation in 30 ml of reaction buffer
containing 10 mlH 2O including approximately 1 mg of recombi-
nant GST or HIS-tagged protein, 10 ml of redissolved protein G
Sepharose beads containing kinases immunoprecipitated from cell
extracts and 10 ml (100 mM Tris pH 7.5, 20 mM MgAc, 0.4–
2 mM ATP, 0,2% ß-mercaptoethanol). For the experiments
shown in Fig. 2A, C, reaction mixtures were spun down and the
supernatants (,30 ml) were incubated with glutathione Sepharose
(GE Healthcare) slurry (equilibrated in cell lysis buffer) at 37uC for
30 min with agitation for purification of the recombinant GST-
tagged protein. Adsorbed GST-fusion proteins were washed three
times with lysis buffer. Finally, beads were boiled for 5 min in 26
Roti-Load and proteins separated by SDS-PAGE and detected by
western blotting. In the experiment shown in Fig. S3A, 5 mCi
c[
32P]ATP were added to the reaction buffer and phosphorylated
proteins were separated by SDS-PAGE and visualized by
autoradiography.
Immunostaining and fluorescence microscopy
HEK293IL-1R cells were cultured in 9,4 mm wells. After 24 h
of transfection, cells were seeded for 24 h in m-slides VI (Ibidi).
After washing, cells were fixed with 4% paraformaldehyde in
Hank’s BSS (PAA Laboratories) for 5 min, blocked with 10%
normal donkey serum (Dianova) for 30 min and incubated with
primary and secondary antibodies diluted in Hank’s BSS
containing 0.1% Saponin (Sigma) for 2 h at room temperature.
The primary antibodies were anti-TAB1 (H-300, Santa Cruz,
1:100), anti-FLAG M2 (F1804, Sigma, 1:100), anti-MYC 9E10
(Roche, 1:200) and anti-P(SS452/3)-TAB1 (1:100). Cy3-congu-
gated (Chemicon, 1:200) and FITC-conjugated (Sigma, 1:100)
secondary antibodies were used. For controls, primary antibodies
were omitted. Nuclei were stained with Hoechst 33342 (Invitro-
gen). Fluorescence imaging was performed on a Leica DM IRE2
fluorescence microscope. Captured images were analysed with the
Leica FW4000 Fluorescence Workstation software.
Immunoblotting and ELISA
Immunoblotting was performed essentially as described [54].
Proteins were separated on 7.5–10% SDS-PAGE and electropho-
retically transferred to PVDF membranes (Millipore). After
blocking with 1% or 5% dried milk in Tris-HCl-buffered saline/
0.05% Tween (TBST) for 1 h, membranes were incubated for 12–
24 h with primary antibodies, washed in TBST and incubated for
1–2 h with the peroxidase-coupled secondary antibody. Proteins
were detected by using enhanced chemiluminescence (ECL)
systems from Pierce, Millipore or GE Healthcare.
Cytokine arrays and ELISA
The mouse cytokine array panel A kit (ARY006) and the mouse
CCL5 duoset (DY478) were used according to the manufacturer’s
instructions (R&D Systems, Inc.).
Ubiquitination assays
Ubiquitination of TAB1 and TAK1 was determined as
described in [15] with the following modifications. Briefly, one
75 cm
2 flask of cells were transfected with 10 mg of expression
vectors for HA-TAK1, MYC-TAB1, p38 MAPK plus MKK62E
(5 mg each) and 20 mg of pDest26-HIS(6)-Ubiquitin or pDest26-
HIS(6). Total amount of DNA was adjusted to 50 mg by adding
pCDNA3.1. After 24 h cells were lysed in 1 ml of lysis buffer (6 M
guanidine-HCl, 0,1 M Na2HPO4/NaH2PO4, 10 mM imidazole,
pH 8.0). Lysates were sonicated to shear DNA and cleared by
centrifugation for 5 min at 15.0006g. 3 mg of lysate protein were
incubated with 50 mlo fN i
2+- NTA agarose for 3 h at room
temperature. Beads were collected by centrifugation, washed twice
in lysis buffer, twice in a buffer containing 1 volumes of lysis buffer
and three volumes of buffer TI (25 mM Tris pH 6.8, 20 mM
imidazole, adjusted to pH 6,8), and twice with buffer TI alone.
Bound proteins were eluted for 5 min at 95uC in SDS PAGE
sample buffer. 120 mg of proteins from the initial lysate (input)
were precipitated by adding one volume of icecold TCA (10%).
The pellet was collected at 15.0006g for 15 min at 4uC, washed
once in two volumes of icecold EtOH (100%), dried in a speed vac
and resuspended in 100 ml of SDS PAGE sample buffer at 95uC
for 5 min. Bound and input protein samples were separated by
8%SDS-PAGE including 4.5% glycerol and analysed by western
blotting.
Supporting Information
Figure S1 Evidence for new phosphorylation sites in
TAB1 in addition to S423, T431 and S438. A) HEK293IL-
1R cells were transiently transfected with expression vectors for
HA-TAB1 wild type, or versions in which S423/T431/S438 (STS)
were mutated to alanine as indicated alone or in combination with
GFP-YopP, FLAG-p38 MAPK plus MKK62E or HA-TAK1. B)
A similar experiment as in A) was performed using a TAB1 mutant
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later, cells were lysed followed by immunoblotting (IB) to detect
HA-TAK1, FLAG-p38 MAPK or HA-TAB1 using the indicated
antibodies. Black arrowheads indicate the three forms of TAB1
(numbered 1–3) with different mobility on SDS-PAGE as
previously described by us [15]. Explanation: As shown in Fig.
S1A, a retarded mobility form 1 of TAB1 is induced by co-
expression of MKK6-p38 MAPK (Fig. S1A, lane 3) or by TAB1-
activated TAK1 (Fig. S1A, lane 4). In the absence of stimulation,
form 2 shows intermediate mobility and represents a constitutive
form of TAB1 which is found in unstimulated cells (Fig. S1A, lane
1). Form 3 of TAB1 displays fastest mobility and is observed by
either mutating S438 (Fig. S1A, lane 13) or by intracellular co-
expression of the bacterial protease YopP (Fig. S1A, lane 2) which
we have shown previously to inhibit the TAK1-MKK6-p38
MAPK pathway [15]. In line with this result, TAB1 form 3 is also
found in cells lacking p38a MAPK or treated with SB203580 [15],
implying that S438 is constitutively phosphorylated by a low level
of active p38 MAPK found in unstimulated cells. However, a
version of TAB1 in which S423, T431 and S438 were mutated to
alanine was still shifted by MKK6-activated p38 MAPK (Fig. S1A,
lane 7) or by TAB1-activated TAK1 (Fig. S1A, lane 8) suggesting
that active p38 MAPK and TAK1 phosphorylate novel sites in
TAB1 in addition to the three well-characterized S423, T431 and
S438 residues.
(TIF)
Figure S2 Validation of phospho-specific antibodies
recognizing phosphorylation of SS452/453 and SS456/
457 of TAB1. HEK293IL-1R cells were transiently transfected
with expression vectors for FLAG-p38 MAPK plus MKK62E (A)
or HA-TAK1 (B, C) in the indicated combinations with wild type
HA-TAB1 (wt) or versions in which serines 452, 453, 456, 457
were point mutated to alanine (A, B) or to glutamic acid (C). 24 h
later, cells were lysed and expression of FLAG-p38 MAPK or HA-
TAK1 and expression or phosphorylation of HA-TAB1 was
analyzed by immunoblotting (IB) using the indicated antibodies.
Black arrowheads indicate forms of TAB1 with different mobility
as described in the legend of Fig. 1. D) Scheme summarizing the
differential effects of MKK62E-p38 MAPK or TAK1-TAB1 on
phosphorylation of individual serines in cluster of aa 452–457.
Explanation: As derived from individual S-A mutations, the
antibodies reacted with all phosphorylated serines and each
residue could be phosphorylated by activated p38 MAPK (Fig.
S2A). Likewise, overexpression of TAK1 and TAB1 caused
phosphorylation of SS452/453 and SS456/457 (Fig. S2B, lane
7). However, in contrast to stimulation of phosphorylations by
active p38 MAPK, mutation of S453 to alanine prevented
phosphorylation at S456/457 (Fig. S2B, lane 9), while mutation
of S456 to alanine significantly weakened phosphorylation at
SS452/453 (Fig. S2C, lane 10). Replacing S453 or S456 by
phosphomimetic glutamic acid residues restored phosphorylation
of neighbouring S456 or S453 residues, respectively, in response to
TAK1 (Fig. S2C, lanes 8, 9). Hence, there is a mutual influence of
phosphorylations within the serine cluster of TAB1 which is only
seen when TAB1 is in complex with TAK1 but not with activated
p38 MAPK, although both kinases can phosphorylate all four
residues in intact cells (summarized in Fig. 2D).
(TIF)
Figure S3 Amino acids 452–457 play only a marginal
role in TAK1 activation and in ubiquitination of the
TAK1-TAB1 complex. A) HEK293IL-1R cells were transiently
transfected with GFP-TAK1 and the indicated TAB1 expression
vectors. 24 h later, cells were lysed, TAK1 was immunoprecipitated
using GFP antibodies and its kinase activity was determined in vitro
using recombinant HIS(6)-MKK6 and
32P-ATP as substrates.
Reaction mixtures were separated on SDS-PAGE and phosphory-
lated MKK6 was detected by autoradiography (left panel) as
described previously [15]. TAK1 and TAB1 proteins and phosphor-
ylated TAK1 contained in the immunoprecipitates were validated
using the indicated antibodies (right panel). B) HA-TAK1 and the
indicated MYC-TAB1 versions were co-transfected with IL-8
promoter luc. constructs. 24 h later, cells were lysed and luciferase
activity was determined. The graph shows the mean +/2 s.e.m. of
the relative IL-8 promoter activity from 5 independent transfections.
As shown in the lower panel for one representative experiment,
lysates were analyzed in parallel for equal expression of transfected
proteins. C) TAB1-deficient Mefs were stably infected with
retroviruses encoding wild type TAB1 or the indicated mutants.
Cells were treated for 30 min with 50 nM calyculin A as indicated or
were left untreated. Lanes 8 and 9 represent samples from wild type
Mefs. The TAK1 complex was immunoprecipitated using TAB2
antibodies as described in [15] and basal TAK1 activity was assessed
by radioactive invitrokinaseassaysasdescribedinA).Lane1indicates
a sample in which the cell extract was omitted in the kinase reaction
to control for autophosphorylation of bacterially expressed HIS(6)-
MKK6. D) HEK293IL-1R cells were transiently transfected with
empty vector or an ubiquitin expression vector (HIS-Ubiquitin) and
combinations of epitope-tagged expression vectors for TAK1, TAB1,
p38 MAPK and MKK62E as indicated. 24 h after transfection, cells
were lysed in denaturing buffer. Ubiquitinated proteins were purified
on Ni
2+-NTA agarose. Lysates and affinity purified proteins were
analyzed by immunoblotting using the indicated antibodies. Details
are described in the methods section and in [15].
(TIF)
Figure S4 TAK1-dependent activation of the CCL5 gene
in A549 cells. A459 lung epithelial carcinoma cells were treated
for 30 min with the TAK1 inhibitor 5Z-7-oxozeaenol (1 mM)
followed by IL-1a (10 ng/ml) for 6 h, IL-1 alone or were left
untreated. Thereafter, CCL5 secretion in the supernatant (A) or
CCL5 mRNA expression (B) were determined by specific ELISA
and RT-qPCR, respectively. Shown are mean values +/2 s.e.m.
form 3 independent experiments.
(TIF)
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